HIPEC During Surgery Improves Long-Term Survival With Stage III Ovarian Cancer
Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves 10-year overall survival in patients with stage III epithelial ovarian cancer by nearly 40%, researchers reported in study findings published in Lancet Oncology.
Race, Age, Chemo, and Other Factors Increase Patients’ Risk for Breast Cancer–Related Lymphedema
Black or Hispanic individuals, those who’ve received neoadjuvant chemotherapy, and older individuals are more likely to experience lymphedema after breast cancer treatment with axillary lymph node dissection and radiation therapy, researchers reported in JAMA Oncology.
Social Determinants Have Clinically Meaningful Effects on Breast Cancer Outcomes
A patient’s race and the neighborhood in which they live can meaningfully lower time to progression and overall survival for triple-negative metastatic breast cancer, oncology nurse researchers reported in the Oncology Nursing Forum.
Inaugural Cancer Moonshot Scholars Cohort Receives First-Year Funding to Advance Cancer Research and Innovation
Committing $5.4 million to their first year of study, the Biden-Harris administration announced its inaugural cohort of 11 Cancer Moonshot scholars in August 2023. The White House said that the emerging leaders in cancer research and innovation will use the funding “to help change what is possible.”
Discoveries in Race-Related Breast Cancer Biomarkers May Improve Precision Treatments
Race-specific cellular and genomic characteristics in breast and breast cancer tissues may explain racial differences in breast cancer aggressiveness, blood vessel growth, tumor cell migration and metastasis, and the cancer pathways GLI1 and Notch, researchers said in study findings published in npj Breast Cancer. The findings may help guide the development of even more personalized treatments and address some aspects of cancer’s disparate burden on certain populations.
Cell-Based Therapy Shows Promise for Chemotherapy-Related Female Infertility
Cellular therapy has revolutionized cancer treatments and outcomes for many patients, and it may one day revolutionize the management of certain side effects as well. According to study findings published in eBioMedicine, induced pluripotent stem cell transplantation may help reverse chemotherapy’s endocrine and reproductive effects on female infertility.
CDC Releases New Data on Cancer Rates Through 2020
After remaining largely stable from 2011–2019, cancer incidence rates dropped sharply in 2020 while mortality remained level, the Centers for Disease Control and Prevention said in its 2023 U.S. Cancer Statistics report.
Endocrine Therapy Break Permits Pregnancies Without Affecting Survivorship Outcomes
Pausing endocrine therapy to give breast cancer survivors an opportunity to attempt pregnancy does not increase their short-term recurrence rates, researchers reported in study findings presented at the 2022 San Antonio Breast Cancer Symposium. Additionally, survivors’ conception rates are on par or higher than those among the general public.
U.S. Preventive Services Task Force Updates Cancer Screening Recommendations
Because of insufficient evidence, the U.S. Preventive Services Task Force’s (USPSTF’s) 2023 skin cancer recommendations advise that “the balance of benefits and harms for visual skin examination by a clinician to screen for skin cancer in asymptomatic adolescents and adults cannot be determined.” For breast cancer, the USPSTF’s 2023 recommendation stated that all women should get screened every other year, starting at age 40.
NIH Acting Director Shares Progress on Novel Nanoparticle for Childhood Cancer Brain Tumor
Noting the complexity of the human brain and brain tumors, Lawrence Tabak, DDS, PhD, acting director of the National Institutes of Health (NIH), discussed in an April 2023 blog post the findings from a NIH-funded research that may suggest novel nanoparticles can help bypass the blood-brain barrier and deliver drugs to treat medulloblastoma, an aggressive brain cancer diagnosed in hundreds of children each year.
Advancements in Childhood Cancer Move Toward Personalized Treatments
Personalizing cancer treatments through targeted drugs and customized doses can make strides in care for pediatric patients with cancer, cancer specialists said in the National Institutes of Health's News in Health.
Platinum Chemo Improves TNBC Survival for Patients Younger Than 50
Adding carboplatin to standard neoadjuvant chemotherapy for patients with triple-negative breast cancer improves complete response, event-free survival, and overall survival, researchers reported in study findings presented in abstract GS5-01 during the 2022 San Antonio Breast Cancer Symposium.
Lung Cancer Screening and Early Detection Drastically Improves Survival Rates
Increases in early-stage lung cancer diagnoses with low-dose computed tomography screening have led to sustained improvements in survival rates more than 20 years later, researchers said while presenting their study findings at the 2022 Radiological Society of North America annual meeting.
Intense, Immediate Research Action in Six Key Areas Can Reduce Cancer’s Impact on All Population Segments, DCCPS Director Says
Marking her first year at the National Cancer Institute (NCI), Katrina Goddard, PhD, director of the NCI’s Division of Cancer Control and Population Sciences, outlined a foundation of future research for DCCPS, priority research areas, and the impact of research on diverse populations in a December 2022 interview.
Pancreatic Cancer Surveillance Programs Lead to Earlier Diagnoses and Better Outcomes
Most patients at high risk for developing pancreatic cancer whose disease was found while participating in a screening program were diagnosed with early-stage cancers, according to study findings published in the Journal of Clinical Oncology.
Cancer Hits Home for NCI Director Bertagnolli
In a December 2022 statement, Monica M. Bertagnolli, MD, National Cancer Institute director, announced that she was diagnosed with hormone receptor-positive, HER2-negative breast cancer and that her prognosis is favorable. She said she is enrolled in a clinical trial centered around her diagnosis to contribute to the cancer knowledge base and advance care.
Aspirin’s Survival Benefits in Advanced CRC Depend on Patient BMI
Regular use of aspirin after an advanced colorectal cancer diagnosis may extend survival by as much as 14 months for patients with a healthy body mass index score prediagnosis compared to those with obese BMIs, researchers reported in JAMA Network Open.
Annual Report to the Nation Says Cancer Deaths Continue Downward Trend
Overall cancer death rates continued to decline from 2015–2019 among men, women, children, adolescents, and young adults in every major racial and ethnic group, according to the October 2022 Annual Report to the Nation on the Status of Cancer. The National Cancer Institute, Centers for Disease Control and Prevention, American Cancer Society, and North American Association of Central Cancer Registries jointly issue the report each year to monitor cancer trends across society.
Text-Messaging Prescreening Streamlines Treatment Visits and Care for ICI Toxicities
Prescreening patients for immune-related adverse events during treatment with immune checkpoint inhibitors using text messaging may reduce the need for some in-person, preinfusion office visits, researchers reported in JAMA Network Open. The approach may help decrease the burden of cancer care for both patients and providers.
Achieve Equity in Patient Communication With These Evidence-Based Approaches
Equalizing the quality of patient-provider communication for Black versus White patients is one way to reduce the systemic racial disparities prevalent in cancer care, researchers reported in study findings published in the November 2022 issue of the Oncology Nursing Forum. They identified critical opportunities for oncology nurses to improve interpersonal communication with Black patients. Nurses are key drivers to affecting change and cancer outcomes for all patients, they reported.
Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment
Compared to their non-Hispanic White counterparts, most Hispanic patients with localized prostate cancer are nearly 20% more likely to have aggressive disease, but the risk varies based on their country of origin, researchers reported in study findings published in Prostate Cancer and Prostatic Diseases. Additionally, they found that the population faces disparities in access to care, with only approximately 60% receiving appropriate treatment.
During or After Chemo, Exercise Fights Fatigue and Supports Cancer Recovery
Patients who engage in physical activity during or after cancer treatment are less fatigued and return to their usual daily activities faster than those who don’t exercise, researchers reported in JACC: CardioOncology. The benefit is highest among patients who are active during treatment but still pronounced for those who resume physical activity after completing treatment.
Rural Patients Who Miss Radiation Doses Are More Likely to Die From Cancer
Regardless of residence, nearly 25% of patients with cancer overall miss at least 10% of the doses in their radiation treatment plans—but the implications on outcomes are far greater for patients living in rural areas than their urban counterparts, according to new research findings published in the International Journal of Radiation Oncology, Biology, Physics.
FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk, BCG Unresponsive, Non–Muscle-Invasive Bladder Cancer
On December 16, 2022, the U.S. Food and Drug Administration approved nadofaragene firadenovec-vncg (Adstiladrin®) for adult patients with high-risk, Bacillus Calmette-Guérin unresponsive, carcinoma in situ, non–muscle-invasive bladder cancer with or without papillary tumors.
Chemo Combo May Be a Bladder Cancer Treatment Alternative During BCG Shortage
Overall survival among patients with non–muscle-invasive bladder cancer who are treated with adjuvant gemcitabine and docetaxel is comparable to overall survival for treatment with bacillus Calmette-Guérin (BCG), researchers reported in the Journal of Urology. The evidence could support a treatment alternative for high-risk patients during the BCG shortage.
Modernized Treatment Approaches for Childhood Cancers Are a Result of COG Clinical Trials
Significant progress has been made with childhood cancer, especially with the efforts of Children's Oncology Group (COG), but some areas still need attention, Doug Hawkins, MD, COG chair, a National Cancer Institute (NCI)-funded network of researchers and hospitals, explained in a September 2022 interview with NCI.
Engaging Community Health Workers Reduces Hospitalizations, Increases Psychosocial, Palliative, and EOL Care
Patients with advanced cancer who met with community health workers between their regular cancer care appointments were less likely to require acute care and more likely to participate in advance care planning and receive mental health, palliative, and hospice care, according to study findings published in JAMA Oncology.
NCI Releases Annual Plan and Budget Proposal for 2024
Along with outlining monetary spending for the upcoming years, the National Cancer Institute’s 2024 annual plan and budget proposal highlights areas of opportunity to advance cancer research, Douglas R. Lowy, MD, who was NCI acting director at the time, said in a September 2022 NCI’s director message.
Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk
Patients with germline genetic variants that increase their risk of developing prostate cancer have a lower risk of developing lethal disease when following a healthy lifestyle, according to study findings that researchers reported in European Urology.
Monica Bertagnolli Delivers First NCI Director’s Report, Outlines Principles to Evolve Cancer Research
In her first report as National Cancer Institute director, Monica M. Bertagnolli, MD, laid out her eight core principles to guide the agency’s work in reformulating clinical trials and strengthening cancer research during the Clinical Trials Advisory Committee meeting in November 2022.
Biomarkers Are Associated With Frailty After Chemo for Breast Cancer
High levels of interleukin-6 (IL-6) and C-reactive protein before chemotherapy for breast cancer may predict a patient’s propensity to develop clinical decline and frailty after treatment, according to study findings that researchers reported in the Journal of Clinical Oncology.
Educational Resources Will Help Biomarkers Have Even More Impact
My passion for biomarkers lies in research, specifically clinical trials. The incorporation of biomarkers in oncology clinical trials has been an important advancement in research, and we’ve seen the effect on improving patient outcomes. Identification of pathogenic variants is essential to prescribing personalized therapy for patients with cancer.
Predictive and Diagnostic Biomarkers
Biomarkers, also called molecular markers or signature molecules, can help clinicians characterize alterations in tumors through the detection of specific DNA, RNA, protein, or metabolomic profiles. These pieces of the cancer puzzle are part of precision oncology that the cancer care team can use to assess patients’ cancer risk and prognosis or monitor disease progression. Biomarkers are also a key factor in determining and tailoring treatment methods and their likelihood of success.
Most Lung Cancer Genetic Variants Are Clinically Actionable and All Patients Should Get Biomarker Testing
More than 95% of germline genetic variants identified through genetic testing in patients with lung cancer are potentially clinically actionable, researchers reported in study findings during the 2022 ASCO Plenary Series Program, leading them to recommend testing all patients with the disease.
Researcher Reflects on How Cancer Was Reported on in the Mid-20th Century
Our understanding of cancer has come a great ways over the past few decades, and some of the progress can be traced back to the 1950’s film Challenge: Science Against Cancer, explained David Cantor, PhD, researcher at the Instituto de Desarrollo Económico y Social, Buenos Aires Argentina, adjunct professor in the School of Public Health at the University of Maryland, College Park, in a July 2022 essay for the National Library of Medicine.
Put Underserved Populations at the Forefront of the Sexual Health Conversation
Cancer and its treatments can affect a patient’s body in many ways, including sexual function. However, the historical evidence base is focused on cisgender men and their sexual health post-cancer treatment, with sexual health of women and LGBTQIA+ patients largely ignored. I, and many others, are working to change these disparities in research and practice.
Tumor-Infiltrating Lymphocytes Activate Immune Response to Metastatic Breast Cancer
More than two-thirds of patients with hormone receptor–positive metastatic breast cancer respond to personalized immunotherapy with tumor-infiltrating lymphocytes and more than half of those treated experience measurable tumor shrinkage, according to study findings published in the Journal of Clinical Oncology.
Hispanic Patients See Highest Increase Among Uterine Cancer’s Growing Mortality Rate
Racial and ethnic groups are disproportionately affected by the increase in uterine cancer mortality in the United States, researchers explained in study findings published in JAMA Oncology, with Hispanic patients experiencing the highest burden.
As Skin Cancer Screening Increases, Clinicians Find More Thin Melanomas
Although regular population-based skin cancer screening isn’t recommended by the U.S. Preventive Services Task Force, more Americans are getting full-body skin exams at dermatology visits or other provider services. Data from a new study published in JAMA Dermatology suggest that the screening uptick is associated with increased diagnoses of early-stage, in situ melanoma, leading the researchers to raise concerns about overdiagnosis.
Single HPV Vaccine Dose May Be Enough to Prevent Cancer
In findings that could have global implications to change the face of female cancers, researchers reported that a single dose of the human papillomavirus (HPV) vaccine is highly effective in protecting young women against cervical infection with cancer-causing HPV types. The study results, which were published in NEJM Evidence, build on the body of evidence supporting single-dose HPV vaccines.
Cost Can Prevent Patients From Receiving Follow-Up Care, Study Suggests
Financial considerations are notable barriers for patients with cancer receiving follow-up cancer care, according to study findings from the National Institutes of Health (NIH) All of Us Research Program.
Cancer Mortality Declines Among Black Patients but Remains Disproportionately High
Death rates fell about 2% per year from 1999–2019 for Black patients with cancer, researchers reported in study findings published in JAMA Oncology; however, the population’s cancer mortality remains higher than other racial and ethnic groups for most cancer sites.
Biden Cancer Moonshot Relaunch Will “End Cancer as We Know It”
In a clarion call for action seven years ago, President Barack Obama unveiled the Cancer Moonshot during his last State of the Union address. In that speech, Obama recalled, “Last year, Vice President Joe Biden said that with a new moonshot, America can cure cancer. Tonight, I’m announcing a new national effort to get it done. And I’m putting Joe in charge of Mission Control.”
Sexual Minority Populations Are Less Likely to Obtain Cervical Cancer Screenings
Propensity to adhere to cervical cancer screening recommendations varies widely by sexual orientation, researchers reported in study findings published in Cancer. They found that those in sexual minority groups are nearly 50% less likely to have ever undergone a Pap test.
Medicaid Expansion Under Affordable Care Act Reduces Health Disparities in Cancer Survival, New Study Suggests
A greater increase in cancer survivorship may be an outcome from Medicaid expansion under the Affordable Care Act (ACA), according to study results published in the Journal of Clinical Oncology in May 2022.
Females Are More Likely to Have Severe Cancer Side Effects Than Males
Broad-based sex differences exist in the severity of side effects from cancer and its treatment, with female patients at an overall 34% higher risk for severe symptoms than male patients—and the risk jumps to nearly 50% for immunotherapies, researchers reported in the Journal of Clinical Oncology.